Back to Journals » Journal of Inflammation Research » Volume 2

Inhibitory effects of zinc hyaluronate on synoviocyte growth and matrix metalloproteinase-9 activity

Authors Saito S, Maekawa K, Kotake S

Published 17 November 2009 Volume 2009:2 Pages 45—57

DOI https://doi.org/10.2147/JIR.S7397

Review by Single anonymous peer review

Peer reviewer comments 3



Seiji Saito, Keisei Maekawa, Shigeru Kotake

Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Abstract: Sodium hyaluronate (Na-HA) is a therapeutic agent used for treating knee arthritis. However, it has been unsuccessfully used in the treatment of knee effusions. Joint effusion results from synovial activation and growth, leading to an increase in the production of matrix metalloproteinases (MMPs), especially MMP-9. This study aimed to determine whether the newly developed zinc hyaluronate (Zn-HA) is more effective than Na-HA in inhibiting the growth of synoviocytes or production and activity of MMPs in rheumatoid synoviocytes. Our results showed that Zn-HA inhibited synoviocyte growth, MMP-9 protein production, and MMP-9 mRNA expression, whereas Na-HA exerted only a slight inhibitory effect on these parameters. Moreover, Zn-HA induced synoviocyte apoptosis, whereas Na-HA did not. These results suggest that Zn-HA retards synoviocyte growth by inducing apoptosis following a decrease in the production of MMP-9 and mRNA. Therefore, it is suggested that Zn-HA can suppress arthritis more efficiently than Na-HA.

Keywords: synoviocyte, apoptosis, sodium hyaluronate, zinc hyaluronate, rheumatoid arthritis, MMP-9

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.